Altea Therapeutics

About:

Altea Therapeutics Corporation develops and commercializes transdermal drug delivery systems.

Website: http://alteatherapeutics.com

Top Investors: Domain Associates, Aperture Venture Partners

Description:

Altea Therapeutics Corporation develops and commercializes transdermal drug delivery systems. It offers PassPort patch, a skin patch that uses short bursts of focused thermal energy to create tiny channels in the surface of the skin and these channels permit the flow of proteins, peptides, carbohydrates, and small molecules into the body without the use of needles. The company also provides Transdermal vaccine patch, a delivery system for water-soluble drugs and proteins; disease prevention products; insulin skin patch, a non-injectable daily insulin product; and opioid patches that provide delivery of opioids and incorporates the layers of deterrents. Altea Therapeutics Corporation was formerly known as Altea Development Corporation. The company was founded in 1998 and is based in Atlanta, Georgia. As of May 9, 2012, Altea Therapeutics Corporation operates as a subsidiary of Nitto Denko Corp.

Total Funding Amount:

$83.5M

Headquarters Location:

Atlanta, Georgia, United States

Founded Date:

1998-01-01

Founders:

Jonathan Eppstein

Number of Employees:

51-100

Last Funding Date:

2010-10-24

IPO Status:

Private

Industries:

© 2025 bioDAO.ai